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Antibiotic-producing microoganisms are a reservoir of drug resistance genes. Studies of the ‘‘antibiotic
resistome’’ can inform antimicrobial drug discovery and explain the emergence of multidrug resistant
pathogens. In this issue of Chemistry & Biology, Westman and colleagues take an alternative look at the
resistome and identify genes that could be used to detoxify the anticancer compound, doxorubicin.This year marks the sixtieth anniversary of
the awarding of the Nobel Prize in medi-
cine or physiology to Selman Waksman
for his discovery of streptomycin, the
first effective treatment for tuberculosis.
The utilization of streptomycin in clinical
settings was a landmark in medicine that
saved millions of lives. Remarkably, the
concepts that Waksman developed and
the strategies that he used to discover
streptomycin (Schatz and Bugle, 1944)
have proven to bemore important inmedi-
cine than the drug itself. Specifically,
Waksman coined the term antibiotic to
describemolecules produced bymicroor-
ganisms that kill or compromise the
growth of other microorganisms. By this
definition, antibiotics represent a large
subset of molecules known as either
natural products or secondary metabo-
lites. He predicted and demonstrated
that antimicrobial drug discovery could
be enabled via systematic isolation of
microorganisms from soil, followed by
assays of their ability to produce antibi-
otics that were toxic to human pathogens.
Waksman’s use of this strategy to dis-
cover two blockbuster antibacterial drugs(streptomycin and neomycin) inspired
countless scientists in industry and
academe whose work has resulted in the
identification of more than 12,000 antibi-
otics (Demain, 1999). Although most of
these molecules are either too toxic for
clinical use or have pharmacological liabil-
ities, a fraction of them are useful asmedi-
cines for the treatment of bacterial and
fungal infections. Although Waksman did
not initially envision it, a subset of antibi-
otics is also used as anticancer drugs
and as immunosuppressants. Suffice to
say, exploitation of antibiotics has revolu-
tionized medicine in many ways.
The growing number of infections and
mortalities caused by multi-drug resistant
bacteria and fungi has renewed interests
in antibiotics from two different perspec-
tives. In one, the rich history of antibiotics
in medicine and the vastness of untapped
biodiversity are used to justify searches
for new molecules from microorganisms
that may be tomorrow’s drugs or drug
leads (Lewis, 2012). Today, the Waksman
drug discovery strategy is being comple-
mented by ‘‘omics’’ approaches wherein
genomes or metagenomes are bioinfor-matically mined in search of genetic
potential for the biosynthesis of novel
antibiotics (Iqbal et al., 2012; Knerr and
van der Donk, 2012). From the other
perspective, antibiotic resistance is of
interest because many antimicrobial
drugs are antibiotics or synthetic deriva-
tives thereof. It is anticipated that knowl-
edge of the molecular mechanisms by
which microorganisms resist antibiotics
could enable the rational design of strate-
gies that will restore the potency or
extend the life span of antimicrobial drugs
(Okandeji et al., 2011). Further, identifica-
tion of antibiotic resistance genes that
render microorganisms insusceptible to
promising drug candidates and subse-
quent determination of the genes’ distri-
bution in bacterial populations could be
used to critical advantage in drug devel-
opment programs (Vecchione and Sello,
2009).
In principle, if one wants to discover
antimicrobial drug resistance genes, then
one could analyze antibiotic-producing
bacteria that must harbor antibiotic resis-
tance genes to avoid suicide. On this
basis, it has been proposed that the
Figure 1. How Does a Bacterium Detoxify an Anticancer Drug?
Encoded by the nuo genes in bacteria, electron transport complex I is a large, membrane-associated
composite of proteins that plays an important role in oxidative phosphorylation. While its physiological
role is to transport electrons from NADH into the electron transport chain, the dehydrogenase encoded
by nuoE, F, and G can also catalyze the reductive deglycosylation of doxorubicin.
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ganisms can be considered a reservoir
of antimicrobial drug resistance genes.
Professor Gerry Wright of McMaster
University has coined the term ‘‘antibiotic
resistome’’ to comprehensively describe
the collection of antibiotic resistance
genes in the environment. In a highly cited
paper, Wright and co-workers reported
that twenty-one antibacterial drug resis-
tance phenotypes and genotypes were
observed in high frequencies among
members of the Streptomyces genus
(D’Costa et al., 2006). These soil-dwelling
bacteria were purposefully selected for
analysis because they are producers of
half of all known antibiotics. The rele-
vance of studies of the antibiotic resis-
tome have been validated by recent
demonstration by Dantas and coworkers
that the genes encoding resistance to
five major classes of antibacterial drugs
(aminoglycosides, amphenicols, b-lac-
tams, sulfonamides, and tetracyclines)
in multiple human pathogens are identical
to those in soil-dwelling bacteria (Fors-
berg et al., 2012). The calculated age of
the antibiotic resistance genes (D’Costaet al., 2011) and their distribution in
bacterial populations (Forsberg et al.,
2012) raise compelling questions about
the mechanisms and evolution of drug
resistance that are under investigation in
many laboratories throughout the world.
In this issue of Chemistry and Biology,
Westman et al. (2012) present a different
objective in mining the antibiotic re-
sistome. Rather than searching for anti-
microbial drug resistance genes, they
sought genes that confer resistance to
antibiotics that are used to treat cancer.
They envision that genes encoding
enzymes that deactivate these antibiotics
via structural modification could be used
to detoxify anticancer drugs in cases of
overdoses, to reduce the side effects of
chemotherapy or to facilitate the disposal
of pharmaceutical waste. In a demon-
stration of their mining strategy, they
screened a library of antibiotic-pro-
ducing actinomycetes and identified a
streptomycete that can detoxify the
anticancer drug doxorubicin. Through
a combination of genome sequencing,
reverse genetic analyses and enzyme
assays, they determined that the resis-Chemistry & Biology 19, October 26, 2012 ªtance of the streptomycete to doxorubicin
is mediated by a cluster of genes (nuoE,
nuoF, and nuoG) encoding the NADH-
dehydrogenase of electron transport
complex I. Interestingly, while its physio-
logical role is in oxidative phosphoryla-
tion, this dehydrogenase adventitiously
catalyzes the reductive deglycosylation
of doxorubicin yielding 7-deoxydoxorubi-
cinolone (Figure 1). Although this dehy-
drogenase-catalyzed mechanism of anti-
cancer drug detoxification has been
reported in humans, the findings reported
in this manuscript are the first to describe
this transformation in bacteria. Based on
the success of this antibiotic resistome
mining approach for the discovery of
enzymes for detoxification of drugs, we
can look forward to new applications
of antibiotic-producing microorganisms
and their genes in medicine and
biotechnology.REFERENCES
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